Cambridge Antibody Technology

Last updated

Cambridge Antibody Technology Group Plc
Company type Private
LSE: CAT Nasdaq: CATG
IndustryBiopharmaceutical
Founded1989;35 years ago (1989) (Daly Laboratories, Babraham)
Founder David Chiswell, Sir Greg Winter, John McCafferty, Medical Research Council
Defunct2007 (2007)
FateAcquired by AstraZeneca in 2006; combined with MedImmune in 2007
Successor MedImmune
Headquarters Granta Park, Cambridgeshire, England, United Kingdom
Area served
Worldwide
Key people
 David Chiswell (CEO 1996–2002)
Peter Chambré (CEO 2003–2006)
Products Adalimumab, discovery of; belimumab discovery of
ServicesTherapeutic monoclonal antibody discovery and development
Revenue£172.50m (six months ending 31 March 2006*)
£147.25m (six months ending 31 March 2006*)
£25.25m (six months ending 31 March 2006*)
Total assets £215.98m (six months ending 31 March 2006*)
Total equity £180.97m (six months ending 31 March 2006*)
OwnerAstraZeneca
Number of employees
Approximately 300 (2006)
Footnotes /references
*Financials for six-month period prior to acquisition by AstraZeneca were distorted by the settlement for royalties payable on Adalimumab sales

Cambridge Antibody Technology Group Plc, (commonly referred to as CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology.

Contents

Phage Display Technology was used by CAT to create adalimumab, the first fully human antibody blockbuster drug. Humira, the brand name of adalimumab, is an anti-TNF antibody discovered by CAT as D2E7, then developed in the clinic and marketed by Abbvie, formerly Abbott Laboratories. CAT was also behind belimumab, the anti-BlyS antibody drug marketed as Benlysta and the first new approved drug for systemic lupus in more than 50 years. [1] In 2018, the Nobel Prize organisation awarded one quarter of the Nobel Prize in Chemistry to a founding member of CAT, Sir Greg Winter FRS "for the phage display of peptides and antibodies.". [2]

Founded in 1989, CAT was acquired by AstraZeneca for £702m in 2006. [3] [4] AstraZeneca subsequently acquired MedImmune LLC, [5] which it combined with CAT to form a global biologics R&D division called MedImmune. [6] CAT was often described as the 'jewel in the crown' of the British biotechnology industry [7] and during the latter years of its existence was the subject of frequent acquisition speculation.

History

CAT was founded in 1989 by Dr. David Chiswell OBE and Sir Greg Winter, with major scientific contributions from Dr. John McCafferty and the Medical Research Council (UK) (MRC). Operations began at the MRC laboratories in Cambridge. In May 1990, operations moved to the Daly Research Laboratories at Babraham Institute, Cambridge. [8]

In 1992, CAT moved to Beech House on the Melbourn Science Park to occupy units B1 and B2. In 1993 the company expanded into unit B3, into B4 into 1995, and in 1998 into units B5, B6, B8 and B9. CAT completed the occupation of Beech House by finally occupying B7 by the late 1990s.

CAT listed on the London Stock Exchange in 1997, raising £43 million, and went through a second round of funding in 2000, raising over £90 million.

In 1999, CAT expanded into a second location in Melbourn called Cambridge House. [9] After leaving Melbourn, CAT sold this location on to housing developers in early 2006. [10]

In 2000, after a succession of deals [11] that focussed on harnessing the exploitation of the human genome, CAT's share price peaked at over £50 per share.

Also in 2000, CAT decided to move out of Melbourn to a science park called Granta Park, roughly 10 miles (16 km) away. [12] [13] Of the buildings on the park, the first to be occupied was the Franklin Building followed, in late 2002, by a move to a new corporate headquarters at the Milstein Building.

The Franklin Building, named after Rosalind Franklin, was formally opened in 2001 by David Sainsbury, Baron Sainsbury of Turville. [14] The Milstein Building was named after César Milstein, and had a modular design with separate laboratory (46,000 sq ft) and administration blocks (21,000 sq ft). [15] In the same year, CAT listed on the NASDAQ.

When AstraZeneca acquired CAT in June 2006, plans were announced to occupy a new building on Granta Park, GP15, offering a further 92,000 sq ft (8,500 m2). Refurbishment of this building took approximately 18 months and the building was officially opened, in November 2008, with the name Aaron Klug Building. [16] [17]

Acquisitions

Aptein Inc.

On 15 July 1998, CAT completed the acquisition of Aptein Inc. [9] This acquisition "...further strengthened its world leading position in antibody display technology...giving CAT controlling patents in the field of polysome display. Polysome display involves the use of polysomes, a type of molecule responsible for protein synthesis within the human body, to display functional antibody proteins in vitro.". Three years later David Glover, CAT's Chief Medical Officer at the time, summarised the acquisition as one which essentially acquired Aptein's patent estate [18]

"Under the terms of the agreement CAT purchased the issued share capital and outstanding share options and warrants of Aptein for a total consideration of up to $11 million satisfied by the issue of up to 2.366 million CAT shares (an implied CAT share price of 278p.) $6 million of the consideration was satisfied by the issue of 1.290 million CAT shares on closing. The balance of the consideration of up to $5 million will be satisfied by the issue of up to 1.076 million CAT shares after Aptein's European patents have been sustained through opposition or appeal. In accordance with accounting standards the cost of acquiring this new technology has been capitalised and will be written off over the lives of the patents concerned.". [19]

Aptein was founded by Glenn Kawasaki, who is currently, amongst other positions, CEO at Accium BioSciences. [20]

According to an article published in Nature in 2002, that focused on the automation of proteomics,..."Normally, an mRNA molecule passes through the ribosome-like ticker-tape and is released, along with the newly synthesised protein molecule, when a sequence of three bases known as a 'stop codon' is reached. In Aptein's technology, stop codons are eliminated so that the completed antibody and its mRNA remain bound together on the ribosome. The system, which CAT is now optimising, is entirely cell-free and so is more amenable to automation. This should make it possible to construct libraries that are orders of magnitude larger than those created using phage display." [21]

CAT published on their optimisation work with Ribosome Display, including:

  • The discovery of tralokinumab, a therapeutic antibody against IL-13. [22]
  • An improved method for eukaryotic ribosome display [23]
  • A comparison of phage and ribosome display approaches for improving antibody affinity and stability showing the advantages of ribosome display [24]
  • The use of ribosome display to optimise pharmacology and "developability" of therapeutic proteins [25]

CAT used extensive data sets from ribosome display to patent protect their anti-IL-13 monoclonal antibody, CAT-354, in a world-first of sequence-activity-relationship claims. [26]

Drug Royalty Corporation Inc.

In 1994, CAT signed a royalty deal with Drug Royalty Corporation Inc. (DRC) such that DRC would receive future royalty revenue from CAT's products.

In January 2002, CAT made a share-based offer to buy DRC for £55 million so that it could buy out this royalty obligation. CAT valued DRC at C$3.00 a share, and this offer was initially recommended by the board of directors of DRC. On 8 March 2002 the investment company Inwest made a competing offer valuing DRC at C$3.05 per share. [27] CAT's offer would see DRC shareholders receiving CAT shares whilst Inwest's offer would see the DRC shareholder receiving cash. DRC's board of directors changed their decision and recommended Inwest's offer. After a number of deadline extensions from CAT the offer from Inwest was accepted by the DRC shareholders. Inwest purchased DRC on 2 May 2002, and the company began operating as a private entity that continues operation today as DRI Capital. [28]

As a result of this failure to purchase DRC, CAT's right to buy back royalty interest was triggered at a cost to CAT of C$14 million (£6.2 million) by way of 463,818 CAT shares. [29]

Oxford Glycosciences

On 23 January 2003 CAT made a share-based offer for Oxford Glycosciences (OGS) [30] and at an Extraordinary General Meeting shareholders voted to approve the merger. In March of this year CAT saw a decline in its share price. Discussions regarding the applicability of the royalty offset provisions for HUMIRA with Abbott Laboratories had started, and these had a negative impact on the CAT share price depressing the value of CAT's offer. [31] [32]

On 26 February 2003 the British-based biotechnology group Celltech subsequently made a hostile £101 million cash offer for OGS [33] and began buying OGS shares. Some reported that this activity represented the UK biotechnology industry's first-ever bidding war. [34] Despite this improved offer from Celltech, OGS continued to recommend the CAT offer. [35]

Celltech continued to buy OGS shares and the OGS board pressed CAT to improve the terms of its offer as the Celltech shareholding reached 10.55%. [36] OGS became alarmed that Celltech's share purchase would prompt CAT to walk away because, under takeover rules, it would not be able to forcibly purchase the 10.55 per cent stake Celltech owned. CAT failed to improve the terms of its bid forcing OGS to abandon the agreement. [37]

Celltech continued buying shares and, as their stake reached 25%, so the board of OGS met to reluctantly recommend the Celltech offer. Celltech completed the purchase of OGS in April 2003. [38] Some newspapers reported that the failure of the bid by CAT would means that CAT would have to cut some of its workforce. [39] Celltech was itself purchased by the Belgian drugmaker UCB in mid-2004. [40]

Genencor

On 1 November 2005 CAT announced it was acquiring two anti-CD22 immunotoxin products from Genencor, namely GCR-3888 and GCR-8015. [41] Genencor is the biotechnology division of Danisco [42] and the acquisition meant CAT would hire certain former Genencor key employees to be responsible for the development of the programmes. [43]

GCR-3888 and GCR-8015 were discovered and initially developed by the National Cancer Institute, which is part of the U.S. National Institutes of Health. Genencor licensed the candidates for hematological malignancies and entered into a Cooperative Research and Development Agreement (CRADA) with the NIH, which will now be continued by CAT. Under the original licence agreement with the NIH, CAT gained the rights to a portfolio of intellectual property associated with the programs and would pay future royalties to the NIH.

CAT intended to file an Investigational New Drug (IND) application for GCR-8015 in various CD22 positive B-cell malignancies, including Non-Hodgkin lymphoma and chronic lymphocytic leukaemia, following a period of manufacturing development which is expected to be complete by the end of 2006 and to support the NCI's ongoing development of GCR-3888 in Hairy cell leukaemia (HCL) and paediatric acute lymphoblastic leukaemia (pALL). [41]

CAT-8015 exhibited a greater affinity for CD22 than its predecessor, CAT-3888 [44] and CAT's language such as "CAT will support the NCI's ongoing development of CAT-3888..." suggested at the time that their focus was on the second generation candidate. [45]

On 16 May 2013, AstraZeneca announced that CAT-8015, now Moxetumumab, [46] has started Phase III clinical trials. [47]

Collaborations

CAT entered into many collaborations with technology and pharmaceutical companies, including:

Products and pipeline

CAT had[ when? ] a number of significant products in the pipeline. These included:

CAT developed their display technologies further into several patented antibody discovery/functional genomics tools which were named Proximol [112] and ProAb. ProAb was announced in December 1997 [113] and involved high throughput screening of antibody libraries against diseased and non-diseased tissue, whilst Proximol used a free radical enzymatic reaction to label molecules in proximity to a given protein. [114] [115]

In September 1999, it was announced that CAT's Library product and ProAb would each receive Millennium Products status. [116] Of the 4,000 products submitted to the Design Council for these awards, 1,012 were chosen and, to attain Millennium Product status, products had to: open up new opportunities, challenge existing conventions, be environmentally responsible, demonstrate the application of new or existing technology, solve a key problem and show clear user benefits. [117]

Patents

CAT pioneered the application of Phage Display and Ribosome Display technology for the design and development of human monoclonal antibody therapeutics and which was reflected in the breadth of the company's patent portfolio. The Cambridge patent portfolio includes about 40 families of patents, covering both technologies and products.

Three main families of major patents cover Cambridge antibody library and Phage Display technology:

'Winter II' and 'Winter/Huse/Lerner' patents cover Medimmune's processes for generating the collections of human antibody genes that comprise MedImmune Cambridge libraries. MedImmune has patents issued in Europe, South Korea, Japan, Australia and the US and a patent application is pending in Canada. These patents are co-owned by the MRC, The Scripps Research Institute and Stratagene and MedImmune currently has exclusive commercial exploitation rights, subject to certain rights held by the Medical Research Council (MRC), Scripps and Stratagene and their pre-existing licensees.

'McCafferty' covers the process by which human antibodies are displayed on phage (Phage Display) and methods of selecting antibodies to desired targets from libraries. MedImmune has patents issued in Europe, Australia, South Korea and Japan and a patent application is pending in Canada. These patents are co-owned by MedImmune and the MRC.

'Griffiths' covers the use of Phage Display technology to isolate human anti-self' antibodies that specifically bind to molecules found in the human body. CAT has patents issued in Australia, Europe and the US and patent applications are pending in Canada and Japan. This patent is co-owned by MedImmune Cambridge and the MRC.

In 2011 "The High Court of England and Wales has ruled that two patents (EP 0774511 and EP 2055777) owned by MedImmune that describe methods of phage display are invalid because of obviousness." [118]

List of Patents

Winter IIWinter/Huse/LernerMcCaffertyGriffithsKawasaki
PCT Publication NumberWO90/05144 [119] WO90/14424 [120] WO90/14430 [121] WO92/01047 [122] WO93/11236 [123] WO91/05058 [124]
USUS6,248,516, US6,545,142US6,291,158, US6,291,159US6,291,160, US6,291,161, US6,680,192US5,969,108, US6,172,197, US6,806,079US5,885,793, US6,521,404, US6,544,731, US6,555,313, US6,593,081, US6,582,915US5,643,768, US5,658,754
EuropeEP0368684EP0472638EP0425661, EP1026239 (pending as of July 2009)EP0589877, EP0774511, EP0844306 (pending as of July 2009)EP0616640, EP1024191 (pending as of July 2009)EP0494955
AustraliaAU0634186AU651065AU643948AU0664155AU0665221AU038762
JapanJP02919890JP33211592-508759JP031769175-509967 (pending as of July 2009)JP03127158, 2000-240298 (pending as of July 2009)
Canada2002868 (pending as of July 2009)CA201684120168422086936 (pending as of July 2009)2124460 (pending as of July 2009)CA2067194
South KoreaKR0184860––KR0222326–KR0185192, KR0204359, KR0204360
DenmarkDK175392–––––

Patent Dispute with MorphoSys

The German biotechnology company MorphoSys generates human antibodies using its phage display-based 'HuCal' (Human Combinatorial Antibody Library) technology. [125] In the late 1990s both companies found themselves jockeying for strong IP position in the area of therapeutic human antibody generation by way of a specific dispute (details on MorphoSys page).

The long, and protracted, dispute resulted which was eventually settled in late 2002 when some argued the settlement was enforced by an industry cash crunch. The 'delighted' CEO at the time, Peter Chambré, reflected that the deal put an end to the distraction to both parties caused by the litigation. [126]

Publications

Scientists at CAT pioneered the use of phage display such that variable antibody domains could be expressed on filamentous phage antibodies, as reported in a key Nature publication, "Phage antibodies: filamentous phage displaying antibody variable domains". [127]

Other key CAT publications included:

Management and notable people

CAT was founded by David Chiswell MBE and Sir Greg Winter, with major scientific contributions from John McCafferty.

Sir Greg Winter FRS is credited with invented techniques to both humanise (1986) and, later, to fully humanise using phage display, antibodies for therapeutic uses. [128] [129] [130] [131] [132] [133] [134] Previously, antibodies had been derived from mice, which made them difficult to use in human therapeutics because the human immune system had anti-mouse reactions to them. [135] [136] [137] [138] [139] For these developments Winter was awarded the 2018 Nobel Prize in Chemistry along with George Smith and Frances Arnold. [140] [141] [142]

Dave Chiswell OBE was responsible for operational management of CAT from 1990 to 2002, including time as chief executive officer from 1996 to 2002. Chiswell announced he was standing down from CAT on 26 November 2001. [143] During his time at CAT, Chiswell had established himself as a significant character in the biotechnology business. [144] In 2003, Chiswell became chairman of the BioIndustry Association, [145] and in June 2006 was awarded an OBE for services to the UK Bioscience Industry in the UK and Overseas. [146]

CAT was governed by a board and, latterly, a Scientific Advisory Board. Members included:

Peter Chambré replaced Dave Chiswell as CEO in early 2002. [152] Chambré had been the CEO of Bespak PLC since May 1994 [153] and, in July 2000, became the chief operating officer of the genomics company Celera. [154] A few years after CAT, Chambré went on to hold a number of roles including director positions at BTG [155] and Spectris, [156] followed by an Industrialist in Residence position at 3i. [157] Chambré went on to executive positions at Cancer Research UK, [158] and more recently, Chambré became Chairman of the Board of Directors at Immatics biotechnologies NV, [159] and Member of the Board of Trustees at Our Future Health. [160]

John McCafferty developed much of the phage display technology used by CAT. McCafferty left CAT to start a group at the Wellcome Trust Sanger Institute where, as part of the ATLAS project, his group demonstrated the potential for large-scale high-throughput generation and validation of monoclonal antibodies. [161] This work built on CAT's ProAb technology. McCafferty founded a new therapeutic antibody discovery biotechnology company, IONTAS Ltd. In 2018, McCafferty's 1990 phage research paper was cited by the Nobel committee when awarding the chemistry prize to Sir Gregory Winter, George Smith and Frances Arnold. [162]

Kevin Johnson joined CAT in 1990, contributed to the discovery of D2E7, played a key role in CAT's initial public offering (IPO) and, by July 1997, was appointed to the Board as Research Director. In 2000, Johnson became Chief Technology Officer responsible for exploitation and development of CAT's technology platforms. In November 2002, CAT announced its intention to seek independent financing for its development of the application of antibodies on microarrays for personalised medicine, as this fell outside CAT's focus on therapeutic antibodies and Johnson positively spearheaded this push. [163] In the event it was not possible to procure finance for this activity and, as a result, microarray activity at CAT was terminated. [164] Johnson is currently a partner at medicxi, a venture capital firm focused on life sciences investments based on the asset-centric approach to investing. [165] [166] He was formerly with Index Ventures, having joined the venture capital firm in 2010. [167] [168]

Jane Osbourn OBE joined CAT as a senior scientist in 1993. [169] Osbourn was a co-author of several, high-impact publications to come out of CAT. When merged with MedImmune, after the acquisition by AstraZeneca, Osbourn became the site leader of MedImmune Cambridge. Osbourn went on to chair the UK's BioIndustry Association in 2015 [170] and, in 2019, was awarded the Order of the British Empire medal for services to "Human Monoclonal Antibody Drug Research and Development and Biotechnology". [171]

Awards

CAT's most significant award was the Prix Galien, [172] awarded for outstanding achievement in product and technology development, in recognition of its creativity in the development of novel human monoclonal antibody therapeutics especially in relation to its product CAT-152, which was used to treat fibrotic scarring in certain ophthalmology conditions. [173]

See also

Related Research Articles

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection. It works by inactivating tumor necrosis factor-alpha (TNFα).

<span class="mw-page-title-main">Gregory Winter</span> English biochemist (born 1951)

Sir Gregory Paul Winter is a Nobel Prize-winning English molecular biologist best known for his work on the therapeutic use of monoclonal antibodies. His research career has been based almost entirely at the MRC Laboratory of Molecular Biology and the MRC Centre for Protein Engineering, in Cambridge, England.

<span class="mw-page-title-main">MedImmune</span> Biopharmaceutical company, acquired by AstraZeneca in 2007

MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca.

Humanized antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibody variants produced naturally in humans. The process of "humanization" is usually applied to monoclonal antibodies developed for administration to humans. Humanization can be necessary when the process of developing a specific antibody involves generation in a non-human immune system. The protein sequences of antibodies produced in this way are partially distinct from homologous antibodies occurring naturally in humans, and are therefore potentially immunogenic when administered to human patients. The International Nonproprietary Names of humanized antibodies end in -zumab, as in omalizumab.

This page provides an alphabetical list of articles and other pages about biotechnology.

Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. It was dropped from further development in favour of fresolimumab, which was being developed by Genzyme as of 2006.

<span class="mw-page-title-main">Tremelimumab</span> Monoclonal antibody

Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma. Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system.

Motavizumab is a humanized monoclonal antibody. It is being investigated by MedImmune for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it was undergoing Phase II and III clinical trials.

Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer. It targets TRAIL-R1, also known as DR4, which is expressed on the surface of many tumor cell types.

An anti-CD22 immunotoxin is a monoclonal antibody linked to a cytotoxic agent. They are being studied in the treatment of some types of B-cell cancer.

John McCafferty is a British scientist, one of the founders of Cambridge Antibody Technology alongside Sir Gregory Winter and David Chiswell. He is well known as one of the inventors of scFv antibody fragment phage display, a technology that revolutionised the monoclonal antibody drug discovery. McCafferty and his team developed this process following failures previously generating antibodies by immunizing mice. Later improvements of antibody phage display technology enables the display of millions of different antibody fragments on the surface of filamentous phage and subsequent selection of highly specific recombinant antibodies to any given target. This technology is widely exploited in pharmaceutical industry for the discovery and development of therapeutic monoclonal antibodies to treat mainly cancer, inflammatory and infectious diseases. One of the most successful was HUMIRA (adalimumab), discovered by Cambridge Antibody Technology as D2E7 and developed and marketed by Abbott Laboratories. HUMIRA, an antibody to TNF alpha, was the world's first phage display derived fully human antibody, which achieved annual sales exceeding $1bn therefore achieving blockbuster status. Humira went on to dominate the best-selling drugs lists - in 2016: The best selling drugs list researched by Genetic Engineering & Biotechnology News, published in March 2017, details that Humira occupied the number 1 position for 2015 and 2016. Whilst for 2017, Abbvie reports that Humira achieved $18.427billion of sales in 2017

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma.

Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.

Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.

<span class="mw-page-title-main">Tralokinumab</span> Monoclonal antibody

Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13.

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2. It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix. Its development has been discontinued.

Jane Osbourn, OBE, is a scientist and former chair of the UK BioIndustry Association.

<span class="mw-page-title-main">Tixagevimab/cilgavimab</span> Monoclonal antibody treatment for COVID-19

Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19. It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. It is co-packaged and given as two separate consecutive intramuscular injections.

References

  1. ↑ "GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta (belimumab) for the treatment of systemic lupus erythematosus". Archived from the original on 17 March 2011. Retrieved 11 March 2011.
  2. ↑ "The Nobel Prize in Chemistry 2018 was divided, one half awarded to Frances H. Arnold "for the directed evolution of enzymes", the other half jointly to George P. Smith and Sir Gregory P. Winter "for the phage display of peptides and antibodies."". nobelprize.org. 3 October 2018.
  3. ↑ "AstraZeneca UK Limited Completes Acquisition of Cambridge Antibody Technology Group plc Compulsory Acquisition Procedure Completed Subsequent Offer Period Closed" (Press release). AstraZeneca. 22 August 2006. Retrieved 8 December 2013.
  4. ↑ "AstraZeneca to buy CAT for £702m". BBC News. 15 May 2006.
  5. ↑ "AstraZeneca International – pharmaceutical company, prescription drugs, medicine manufacturers". Astrazeneca.com. 19 June 2007. Archived from the original on 13 January 2010. Retrieved 12 May 2010.
  6. ↑ "MEDIMMUNE LIMITED, company number 02451177, credit report, annual accounts from Companies House and free company monitoring". Ukdata.com. 31 December 2008. Archived from the original on 26 April 2008. Retrieved 12 May 2010.
  7. ↑ "Investment: The drugs don't work". The Independent. London. 22 August 2008. Retrieved 1 April 2010.
  8. ↑ "Launch of Babraham BioConcepts Ltd – £1 million investment by Avlar BioVentures". Babraham.ac.uk. 5 September 2006. Archived from the original on 8 September 2010. Retrieved 12 May 2010.
  9. 1 2 "MedImmune" (PDF). Cambridgeantibody.com. Retrieved 12 May 2010.[ permanent dead link ]
  10. ↑ "Twenty homes plan for research building site | Cambridge City News, Cambridge Local News Stories & Latest Headlines About Cambridge". Cambridge-news.co.uk. 23 January 2006. Archived from the original on 22 July 2012. Retrieved 5 October 2013.
  11. ↑ Shah, Saeed (2 March 2000). "Cambridge Antibody shares soar 58% as investors applaud move to exploit genes". The Independent. London. Retrieved 1 April 2010.[ dead link ]
  12. ↑ "Offices To Let/Rent | Business Parks, Science Parks, Industrial Estates". MEPC. Archived from the original on 6 January 2009. Retrieved 12 May 2010.
  13. ↑ "Cambridgeshire". Ukbusinesspark.co.uk. Archived from the original on 15 February 2012. Retrieved 12 May 2010.
  14. ↑ "Offices To Let/Rent | Business Parks, Science Parks, Industrial Estates". MEPC. Archived from the original on 6 January 2009. Retrieved 12 May 2010.
  15. ↑ "Demonstration Projects | Project Details". Constructing Excellence. 6 March 2006. Archived from the original on 3 October 2011. Retrieved 12 May 2010.
  16. ↑ "Home | InPharm". Pharmafocus.com. Retrieved 12 May 2010.
  17. ↑ "Offices To Let/Rent | Business Parks, Science Parks, Industrial Estates". MEPC. Retrieved 12 May 2010.[ permanent dead link ]
  18. ↑ "Articles: Interview With Cambridge Antibody Technology Medical Director David Glover". Pharmalicensing.com. 6 March 2002. Archived from the original on 3 February 2010. Retrieved 12 May 2010.
  19. ↑ http://www.cambridgeantibody.com/__data/assets/pdf_file/5246/catannualreport1998.pdf%7C [ permanent dead link ] page 29 of the CAT Annual Report 1998
  20. ↑ "Management". Acciumbio.com. Archived from the original on 14 October 2008. Retrieved 12 May 2010.
  21. ↑ Abbott, Alison (January 2002). "Betting on tomorrow's chips". Nature. 415 (6868): 112–114. Bibcode:2002Natur.415..112A. doi: 10.1038/415112a . PMID   11805803. S2CID   4412646.
  22. 1 2 Thom, G.; Cockroft, A. C.; Buchanan, A. G.; Joberty Candotti, C.; Cohen, E. S.; Lowne, D.; Monk, P.; Shorrock-Hart, C. P.; Jermutus, L.; Minter, R. R. (9 May 2006). "Probing a protein-protein interaction by in vitro evolution". Proceedings of the National Academy of Sciences. 103 (20): 7619–7624. Bibcode:2006PNAS..103.7619T. doi: 10.1073/pnas.0602341103 . PMC   1458619 . PMID   16684878.
  23. ↑ Douthwaite, J.A.; Groves, M.A.; Dufner, P.; Jermutus, L. (February 2006). "An improved method for an efficient and easily accessible eukaryotic ribosome display technology". Protein Engineering, Design and Selection. 19 (2): 85–90. doi: 10.1093/protein/gzj003 . PMID   16368721.
  24. ↑ Dufner, Patrick; Jermutus, Lutz; Minter, Ralph R. (November 2006). "Harnessing phage and ribosome display for antibody optimisation". Trends in Biotechnology. 24 (11): 523–529. doi:10.1016/j.tibtech.2006.09.004. PMID   17000017.
  25. ↑ Buchanan, A.; Ferraro, F.; Rust, S.; Sridharan, S.; Franks, R.; Dean, G.; McCourt, M.; Jermutus, L.; Minter, R. (31 August 2012). "Improved drug-like properties of therapeutic proteins by directed evolution". Protein Engineering Design and Selection. 25 (10): 631–638. doi:10.1093/protein/gzs054. PMC   3449403 . PMID   22942395.
  26. ↑ Monk, Phillip; Jermutus, Lutz; Minter, Ralph; Shorrock, Celia (28 January 2005), Human Antibody Molecules for Il-13 , retrieved 7 February 2016
  27. ↑ "Drug Royalty's B of D Recommends Inwest Cash Offer". Archived from the original on 3 October 2008. Retrieved 18 August 2009.
  28. ↑ "DRI to seek $1bn for third fund". Private Equity International. 10 July 2012. Retrieved 5 October 2013.
  29. ↑ http://www.cambridgeantibody.com/__data/assets/pdf_file/5248/interim_report_2002.pdf%7C [ permanent dead link ] page 5 of CAT's 2002 Interim Report
  30. ↑ "Cambridge Antibody to merge with Oxford Glycosciences. – Free Online Library". Thefreelibrary.com. Retrieved 12 May 2010.
  31. ↑ Foley, Stephen (27 March 2003). "CAT's bid hopes floored by royalties dispute". The Independent. London. Retrieved 1 April 2010.[ dead link ]
  32. ↑ page 4 of CAT's 2003 Interim Report [ permanent dead link ]
  33. ↑ "UCB ::: Investor Relations – Press Releases – UCB – News Release". Ir.ucb-group.com. Retrieved 12 May 2010.
  34. ↑ "drug discovery@nature.com". Nature. Retrieved 12 May 2010.
  35. ↑ Foley, Stephen (27 February 2003). "Oxford Glyco turns down higher bid to stick with CAT". The Independent. London. Retrieved 1 April 2010.[ dead link ]
  36. ↑ Griffiths, Katherine (24 March 2003). "OGS presses CAT to improve offer". The Independent. London. Retrieved 1 April 2010.[ dead link ]
  37. ↑ Foley, Stephen (15 March 2003). "Oxford Glyco seeks bidders as CAT offer's value falls". The Independent. London. Retrieved 1 April 2010.[ dead link ]
  38. ↑ Foley, Stephen (12 April 2003). "Celltech wins bid battle for Oxford GlycoSciences". The Independent. London. Retrieved 1 April 2010.[ dead link ]
  39. ↑ Foley, Stephen (20 May 2003). "CAT forced to cut back research after Oxford Glyco bid fails". The Independent. London. Archived from the original on 24 April 2010. Retrieved 1 April 2010.
  40. ↑ "UCB ::: Investor Relations – Press Releases – UCB – News Release". Ir.ucb-group.com. 9 July 2004. Retrieved 12 May 2010.
  41. 1 2 3 "Cambridge Antibody Technology Acquires Oncology Product Candidates from Genencor". PR Newswire. Archived from the original on 2 August 2009. Retrieved 12 May 2010.
  42. ↑ "About Genencor". Archived from the original on 7 January 2009. Retrieved 12 August 2009.
  43. ↑ "Food ingredient solutions - DuPont | Danisco". www.danisco.com. Archived from the original on 20 January 2013. Retrieved 27 January 2022.
  44. ↑ "News Releases – National Cancer Institute". Press.nci.nih.gov. 1 January 1980. Retrieved 12 May 2010.
  45. ↑ "Cambridge Antibody Technology Announces Preliminary Results for the Year Ended 30 September 2005. | Goliath Business News". Goliath.ecnext.com. Archived from the original on 31 October 2021. Retrieved 12 May 2010.
  46. ↑ "moxetumomab () UKMi New Drugs Online Database". Ukmi.nhs.uk. 30 April 2013. Archived from the original on 3 March 2016. Retrieved 5 October 2013.
  47. ↑ Connolly, Allison (16 May 2013). "AstraZeneca Advances Three Cancer Drugs into Late-Stage Trials". Bloomberg. Retrieved 5 October 2013.
  48. ↑ "Searle and Cambridge Combine Efforts – develop monoclonal antibody-based therapeutic drugs – Brief Article | Find Articles at BNET". 2000. Retrieved 12 May 2010– via Find Articles.
  49. ↑ "Monsanto and Pharmacia & Upjohn to Merge, Creating Global Leader in Pharmaceuticals With Top-Tier Growth Prospects". .prnewswire.com. 19 December 1999. Archived from the original on 16 July 2011. Retrieved 12 May 2010.
  50. ↑ "and Pharmacia | Pfizer: the world's largest research-based pharmaceutical company". Pfizer. Archived from the original on 19 March 2013. Retrieved 12 May 2010.
  51. ↑ "Technology Collaborations – Hgs". Hgsi.com. 7 February 2008. Archived from the original on 5 August 2010. Retrieved 12 May 2010.
  52. ↑ "MedImmune". Cambridgeantibody.com. Retrieved 12 May 2010.[ permanent dead link ]
  53. ↑ "GSK completes acquisition of Human Genome Sciences | GlaxoSmithKline". Gsk.com. Archived from the original on 4 October 2013. Retrieved 5 October 2013.
  54. ↑ "BENLYSTA (belimumab) – HGS". Hgsi.com. Archived from the original on 20 November 2008. Retrieved 12 May 2010.
  55. ↑ "GlaxoSmithKline (GSK) – global healthcare company. Do more, feel better, live longer". Hgsi.com. Archived from the original on 25 December 2011. Retrieved 5 October 2013.
  56. ↑ "FDA approves Benlysta to treat lupus". Fda.gov. 9 March 2011. Retrieved 5 October 2013.
  57. ↑ "Raxibacumab – HGS". Hgsi.com. Archived from the original on 28 July 2011. Retrieved 12 May 2010.
  58. ↑ "GSK announces FDA Advisory Committee vote in favour of raxibacumab for the treatment of inhalational anthrax infection | GlaxoSmithKline". Gsk.com. Archived from the original on 4 October 2013. Retrieved 5 October 2013.
  59. ↑ "TRAIL Receptor Antibodies – HGS". Hgsi.com. Archived from the original on 16 May 2008. Retrieved 12 May 2010.
  60. ↑ Pukac, L; Kanakaraj, P; Humphreys, R; Alderson, R; Bloom, M; Sung, C; Riccobene, T; Johnson, R; Fiscella, M; Mahoney, A; Carrell, J; Boyd, E; Yao, X T; Zhang, L; Zhong, L; von Kerczek, A; Shepard, L; Vaughan, T; Edwards, B; Dobson, C; Salcedo, T; Albert, V (20 April 2005). "HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo". British Journal of Cancer. 92 (8): 1430–1441. doi:10.1038/sj.bjc.6602487. PMC   2361994 . PMID   15846298.
  61. ↑ http://www.trailr2mab.com/news/press/02-01-08_trail_cat.html [ permanent dead link ]
  62. ↑ Murray-West, Rosie (29 September 2000). "CAT leaps on tie-up deal with Genzyme". The Daily Telegraph. London. Retrieved 1 April 2010.
  63. ↑ "Cambridge Antibody, Genzyme to collaborate on human anti-TGFBeta". Drugdiscoveryonline.com. 2 October 2000. Retrieved 12 May 2010.
  64. ↑ "Genzyme General and Cambridge Antibody Technology To Collaborate on Development of Human Anti-TGF-beta Monoclonal Antibodies". Prnwire.com. Retrieved 12 May 2010.
  65. ↑ Grutter, C.; Wilkinson, T.; Turner, R.; Podichetty, S.; Finch, D.; McCourt, M.; Loning, S.; Jermutus, L.; Grutter, M. G. (2008). "A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions". Proceedings of the National Academy of Sciences. 105 (51): 20251–20256. Bibcode:2008PNAS..10520251G. doi: 10.1073/pnas.0807200106 . PMC   2600578 . PMID   19073914.
  66. ↑ "Genzyme's Research and Development – Technology Platforms". Genzyme.com. Archived from the original on 4 January 2010. Retrieved 12 May 2010.
  67. 1 2 "Home – Sanofi". genzymeoncology.com. Archived from the original on 16 May 2008. Retrieved 25 July 2009.
  68. ↑ "Cambridge Antibody Technology Group PLC Takeover Gives Genzyme Corporation Buyout Rights To Drug – News, Search Jobs, Events". Biospace.com. 15 May 2006. Archived from the original on 16 July 2011. Retrieved 12 May 2010.
  69. 1 2 "Sanofi-Aventis to buy Genzyme in search for new sales". BBC. 16 February 2011. Retrieved 5 October 2013.
  70. ↑ Cambridge Antibody Technology Partners With Immunex Corporation to Develop Novel Human Monoclonal Antibodies. – PR Newswire Online Press Releases, 1 December 2000
  71. ↑ "Cambridge Antibody Technology, Immunex to co-develop human". Drugdiscoveryonline.com. 21 May 2001. Retrieved 12 May 2010.
  72. ↑ Mesure, Susie (22 May 2001). "CAT signs deal with Immunex to share R&D costs". The Independent. London. Retrieved 1 April 2010.[ dead link ]
  73. ↑ "Media – Press Release". Amgen. 16 July 2002. Retrieved 12 May 2010.
  74. ↑ Foley, Stephen (26 December 2003). "CAT ties up skin treatments deal with Amgen". The Independent. London. Retrieved 1 April 2010.[ dead link ]
  75. ↑ "Cambridge Antibody Technology/Amgen Restructure Agreement. – Free Online Library". Thefreelibrary.com. 1 February 2004. Retrieved 12 May 2010.
  76. ↑ "Amgen – Media – Press Release". Xt.amgen.com. Retrieved 12 May 2010.
  77. ↑ "Science – Pipeline". Amgen. 5 February 2010. Retrieved 12 May 2010.
  78. 1 2 "Cambridge Antibody Technology and AMRAD to develop antibody therapeutics. | Europe – Western Europe from". AllBusiness.com. Retrieved 12 May 2010.
  79. ↑ "BioMelbourne: AMRAD changes name to Zenyth Therapeutics". Archived from the original on 9 October 2006. Retrieved 28 July 2009.
  80. ↑ "News Archive". Csl.com.au. 17 July 2006. Archived from the original on 30 October 2010. Retrieved 12 May 2010.
  81. ↑ "CSL" (PDF). csl.com.au.
  82. ↑ "Abbott Completes Separation of Research-Based Pharmaceuticals Business| January 2, 2013". Abbott.com. Archived from the original on 11 September 2013. Retrieved 5 October 2013.
  83. ↑ "The Top 15 Best-Selling Drugs of 2016 – The Lists – GEN". GEN. 6 March 2017.
  84. ↑ "AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results – AbbVie News Center". news.abbvie.com. Archived from the original on 12 April 2018. Retrieved 8 March 2018.
  85. ↑ "Abbott 2007 Annual Report : Pharmaceuticals". Abbott.com. Archived from the original on 31 July 2010. Retrieved 12 May 2010.
  86. ↑ Abbott Reports Psoriasis Phase III Results of its Investigational IL-12/23 Inhibitor Briakinumab (ABT-874)
  87. ↑ "Genzyme Oncology Clinical Trial Details". Genzymeoncology.com. Archived from the original on 11 July 2011. Retrieved 12 May 2010.
  88. ↑ Foley, Stephen (10 February 2004). "CAT may abandon skin drug after trial results disappoint". The Independent. London. Archived from the original on 3 November 2012. Retrieved 1 April 2010.
  89. ↑ "Sanofi – R&D portfolio". En.sanofi.com. 2 September 2013. Retrieved 5 October 2013.
  90. ↑ "IngentaConnect Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody – Cambridge". Ingentaconnect.com. Retrieved 12 May 2010.
  91. ↑ Cordeiro, MF (2003). "Technology evaluation: lerdelimumab, Cambridge Antibody Technology" (Free full text). Current Opinion in Molecular Therapeutics. 5 (2): 199–203. PMID   12772512.
  92. ↑ "CAT abandons Trabio after second clinical trial failure. | Goliath Business News". Goliath.ecnext.com. 28 March 2005. Retrieved 12 May 2010.
  93. ↑ Ding, C; Li, J; Zhang, X (2004). "Bertilimumab Cambridge Antibody Technology Group". Current Opinion in Investigational Drugs. 5 (11): 1213–8. PMID   15573873.
  94. ↑ "iCo Therapeutics Inc – Pipeline". Icotherapeutics.com. Archived from the original on 27 April 2011. Retrieved 12 May 2010.
  95. ↑ "Business News, Cambridge and UK business news | Wonder drug promise to help with arthritis". Cambridge-news.co.uk. Archived from the original on 23 July 2012. Retrieved 12 May 2010.
  96. ↑ "MedImmune | R&D Pipeline | Phase 1 Drugs". www.medimmune.com. Archived from the original on 29 June 2009.
  97. ↑ "A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis – Full Text View". ClinicalTrials.gov. Retrieved 12 May 2010.
  98. ↑ "Rheumatology – Respiratory & inflammation – Therapy area review – Directors' Report – AstraZeneca Annual Report 2008". Astrazeneca-annualreports.com. Archived from the original on 2 April 2010. Retrieved 12 May 2010.
  99. ↑ http://www.medimmune.com/press/fullstory.asp?reqid=1080894&yr=2007 [ dead link ]
  100. ↑ https://investors.kiniksa.com/node/7611/html [ bare URL ]
  101. ↑ "Kiniksa Outlines Next Steps for the Development of Mavrilimumab | Kiniksa Pharmaceuticals".
  102. ↑ "ADTRALZA Trademark of LEO Pharma A/S. Application Number: 018002939 :: Trademark Elite Trademarks".
  103. ↑ "Our Pipeline | Biopharmaceutical Process". MedImmune. Archived from the original on 3 April 2013. Retrieved 5 October 2013.
  104. ↑ "AstraZeneca enters licensing agreements with LEO Pharma in skin diseases".
  105. ↑ "LEO Pharma starts phase 3 clinical study for tralokinumab in atopic dermatitis". leo-pharma.com. Archived from the original on 31 July 2019. Retrieved 31 July 2019.
  106. ↑ "LEO Pharma receives positive CHMP opinion of Adtralza® (Tralokinumab) for the treatment of adults with moderate-to-severe atopic dermatitis | LEO Pharma".
  107. ↑ "LEO Pharma announces European Commission approval of Adtralza® (Tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis".
  108. 1 2 "MedImmune" (PDF). Cambridgeantibody.com. Archived from the original (PDF) on 27 February 2007. Retrieved 12 May 2010.
  109. ↑ "MedImmune | R&D Pipeline | Cambridge UK Pipeline". Archived from the original on 26 December 2008. Retrieved 12 August 2009.
  110. ↑ FDA approves new kind of treatment for hairy cell leukemia Sept 2018
  111. ↑ "Reuters.com". Reuters. Archived from the original on 7 September 2012. Retrieved 12 May 2010.
  112. ↑ Osbourn, JK (2002). "Proximity-guided (ProxiMol) antibody selection". Antibody Phage Display (Free full text). Methods in Molecular Biology. Vol. 178. pp. 201–5. doi:10.1385/1-59259-240-6:201. ISBN   978-1-59259-240-1. PMID   11968489.
  113. ↑ "Cambridge Antibody Technology". Ukbusinesspark.co.uk. Archived from the original on 28 September 2011. Retrieved 12 May 2010.
  114. ↑ Osbourn, Jane K; Derbyshire, Elaine J; Vaughan, Tristan J; Field, Anne W; Johnson, Kevin S (January 1998). "Pathfinder selection: in situ isolation of novel antibodies". Immunotechnology. 3 (4): 293–302. doi:10.1016/S1380-2933(97)10007-0. PMID   9530562.
  115. ↑ "CHI's Molecular Med Monthly Articles". Chidb.com. Archived from the original on 8 October 2011. Retrieved 12 May 2010.
  116. ↑ http://www.prnewswire.ae/cgi/news/release?id=54703 [ permanent dead link ]
  117. ↑ "UK Government Web Archive". Archived from the original on 3 March 2010. Retrieved 5 April 2017.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  118. ↑ "Patent watch". Nature Reviews Drug Discovery. 10 (8): 568–569. 2011. doi:10.1038/nrd3529. S2CID   860110.
  119. ↑ "Espacenet Bibliographic data". Espacenet. 17 May 1990. Retrieved 12 May 2010.
  120. ↑ "Espacenet Bibliographic data". Espacenet. 29 November 1990. Retrieved 12 May 2010.
  121. ↑ "Espacenet Bibliographic data". Espacenet. 29 November 1990. Retrieved 12 May 2010.
  122. ↑ "Espacenet Bibliographic data". Espacenet. 23 January 1992. Retrieved 12 May 2010.
  123. ↑ "Espacenet Bibliographic data". Espacenet. 10 June 1993. Retrieved 12 May 2010.
  124. ↑ "Espacenet Bibliographic data". Espacenet. 18 April 1991. Retrieved 12 May 2010.
  125. ↑ "Advantages of Human Antibodies > Technologies > MorphoSys". Archived from the original on 23 June 2009. Retrieved 13 August 2009.
  126. ↑ Mitchell, Peter (February 2003). "Cash crunch quells antibody litigation". Nature Biotechnology. 21 (2): 114–115. doi:10.1038/nbt0203-114. PMID   12560822. S2CID   26354552.
  127. ↑ McCafferty, John; Griffiths, Andrew D.; Winter, Greg; Chiswell, David J. (December 1990). "Phage antibodies: filamentous phage displaying antibody variable domains". Nature. 348 (6301): 552–554. Bibcode:1990Natur.348..552M. doi:10.1038/348552a0. PMID   2247164. S2CID   4258014.
  128. ↑ The Scientific Founders Archived 13 September 2011 at the Wayback Machine of Bicycle Therapeutics Ltd. – Christian Heinis and Sir Greg Winter, FRS.
  129. ↑ McCafferty, J.; Griffiths, A.; Winter, G.; Chiswell, D. (1990). "Phage antibodies: filamentous phage displaying antibody variable domains". Nature. 348 (6301): 552–554. Bibcode:1990Natur.348..552M. doi:10.1038/348552a0. PMID   2247164. S2CID   4258014.
  130. ↑ www.trin.cam.ac.uk Archived 6 March 2012 at the Wayback Machine
  131. ↑ Cambridge Antibody Technology's publications indexed by the Scopus bibliographic database. (subscription required)
  132. ↑ Winter, G; Griffiths, A. D.; Hawkins, R. E.; Hoogenboom, H. R. (1994). "Making antibodies by phage display technology". Annual Review of Immunology. 12: 433–455. doi:10.1146/annurev.iy.12.040194.002245. PMID   8011287.
  133. ↑ Griffiths, A. D.; Williams, S. C.; Hartley, O; Tomlinson, I. M.; Waterhouse, P; Crosby, W. L.; Kontermann, R. E.; Jones, P. T.; Low, N. M.; Allison, T. J. (1994). "Isolation of high affinity human antibodies directly from large synthetic repertoires". The EMBO Journal. 13 (14): 3245–60. doi:10.1002/j.1460-2075.1994.tb06626.x. PMC   395221 . PMID   8045255.
  134. ↑ Hoogenboom, H. R.; Griffiths, A. D.; Johnson, K. S.; Chiswell, D. J.; Hudson, P.; Winter, G. (1991). "Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains". Nucleic Acids Research. 19 (15): 4133–4137. doi:10.1093/nar/19.15.4133. PMC   328552 . PMID   1908075.
  135. ↑ Anon (2011). "The inventor of humanized monoclonal antibodies and cofounder of Cambridge Antibody Technology, Greg Winter, muses on the future of antibody therapeutics and UK life science innovation". Nature Biotechnology . 29 (3): 190. doi: 10.1038/nbt.1815 . PMID   21390009. S2CID   205275386.
  136. ↑ Winter, G.; Fields, S.; Brownlee, G. G. (1981). "Nucleotide sequence of the haemagglutinin gene of a human influenza virus H1 subtype". Nature. 292 (5818): 72–5. Bibcode:1981Natur.292...72W. doi:10.1038/292072a0. PMID   7278968. S2CID   4312205. Closed Access logo transparent.svg
  137. ↑ Fields, S.; Winter, G.; Brownlee, G. G. (1981). "Structure of the neuraminidase gene in human influenza virus A/PR/8/34". Nature . 290 (5803): 213–7. Bibcode:1981Natur.290..213F. doi:10.1038/290213a0. PMID   7010182. S2CID   8051512. Closed Access logo transparent.svg
  138. ↑ Riechmann, L.; Clark, M.; Waldmann, H.; Winter, G. (1988). "Reshaping human antibodies for therapy". Nature. 332 (6162): 323–7. Bibcode:1988Natur.332..323R. doi: 10.1038/332323a0 . PMID   3127726. S2CID   4335569. Closed Access logo transparent.svg
  139. ↑ Marks, J. D.; Hoogenboom, H. R.; Bonnert, T. P.; McCafferty, J.; Griffiths, A. D.; Winter, G. (1991). "By-passing immunization". Journal of Molecular Biology . 222 (3): 581–97. doi:10.1016/0022-2836(91)90498-U. PMID   1748994. Closed Access logo transparent.svg
  140. ↑ "Live blog: direction evolution takes chemistry Nobel prize" . Retrieved 3 October 2018.
  141. ↑ "Nobel Prize in Chemistry 2018 – live". The Guardian. 3 October 2018. Retrieved 3 October 2018.
  142. ↑ "The Nobel Prize in Chemistry 2018 was divided, one half awarded to Frances H. Arnold "for the directed evolution of enzymes", the other half jointly to George P. Smith and Sir Gregory P. Winter "for the phage display of peptides and antibodies."". nobelprize.org. 3 October 2018.
  143. ↑ Lambeth, Jonathan (27 November 2001). "Chiswell to quit Cambridge". The Daily Telegraph. London. Retrieved 4 September 2013.
  144. ↑ "Trust me, I'm the CAT doctor". The Independent. London. 5 April 2000. Retrieved 1 April 2010.[ dead link ]
  145. ↑ http://www.bioindustry.org/cgi-bin/contents_view.pl [ dead link ]
  146. ↑ "No. 58014". The London Gazette (Supplement). 17 June 2006. p. 9.
  147. ↑ "César Milstein – Autobiography". Nobel Foundation. Retrieved 12 May 2010.
  148. ↑ "MedImmune". Cambridgeantibody.com. Archived from the original on 28 August 2008. Retrieved 12 May 2010.
  149. ↑ "Fellows of UCL". University College London. Archived from the original on 22 January 2009. Retrieved 12 May 2010.
  150. ↑ "CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC (CAT) PRELIMINARY STATEMENT OF RESULTS". Archived from the original on 1 December 2008. Retrieved 25 July 2009.
  151. ↑ "Silicon Fen Business Report – CAT recommends AstraZeneca's £702m bid; major R&D centre in Cambridge planned". Siliconfenbusiness.com. 15 May 2006. Retrieved 12 May 2010.[ dead link ]
  152. ↑ Foley, Stephen (26 February 2002). "Genome chief Chambre hired to turn Cambridge into profit". The Independent. London. Retrieved 1 April 2010.[ dead link ]
  153. ↑ Stevenson, Tom (8 January 1997). "The Investment Column: Bespak investors can breathe easy". The Independent. London. Retrieved 1 April 2010.
  154. ↑ "Celera Genomics Appoints Chief Operating Officer; Peter Chambre, CEO of Bespak plc to Lead Operations. – Business Wire". 3 July 2000.
  155. ↑ "Peter Alan CHAMBRE personal appointments - Find and update company information - GOV.UK".
  156. ↑ "Peter Alan CHAMBRE personal appointments - Find and update company information - GOV.UK".
  157. ↑ https://scrip.pharmaintelligence.informa.com/MT048579/PEOPLE---UK-private-equity-and-venture-capital-firm-3I-makes-appointment [ bare URL ]
  158. ↑ "Our Trustees". 8 October 2013.
  159. ↑ "Peter Chambré".
  160. ↑ "New Trustees join the Board of Our Future Health today".
  161. ↑ "About The Sanger Institute – Wellcome Trust Sanger Institute". Sanger.ac.uk. 16 April 2010. Retrieved 12 May 2010.
  162. ↑ "Dr John McCafferty on how his antibody phage display work contributed to a Nobel Prize". Next Generation Therapeutics.
  163. ↑ Mitchell, Peter (March 2002). "A perspective on protein microarrays". Nature Biotechnology. 20 (3): 225–229. doi:10.1038/nbt0302-225. PMID   11875416. S2CID   5603911.
  164. ↑ http://www.cambridgeantibody.com/__data/assets/pdf_file/5247/interim_report_2003.pdf%7C [ permanent dead link ] page 4 of CAT's Interim report
  165. ↑ "Backed by J&J and Glaxo, veteran VC group splits from Index, unveils $227M fund". FierceBiotech. 1 February 2016.
  166. ↑ "J&J and GSK join Medicxi's European life sciences push". FT. 2 February 2016.
  167. ↑ "Index Ventures appoints antibody expert as partner". MedNous. 3 September 2010.
  168. ↑ "News". Index Ventures. Archived from the original on 14 February 2014. Retrieved 31 July 2012.
  169. ↑ "Dr Jane Osbourn of AstraZeneca and UK BioIndustry Association thanks colleagues as she is made an OBE". 7 June 2019.
  170. ↑ "MedImmune's Jane Osbourn announced as new BIA chair alongside new board appointments".
  171. ↑ "The Queen's Birthday Honours List 2019".
  172. ↑ Prix Galien information Archived 21 September 2008 at the Wayback Machine .
  173. ↑ CAT Prix Galien news release
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.